Anish M. John - 01 Jun 2022 Form 3 Insider Report for Oncocyte Corp (OCX)

Role
SVP, Finance, and Interim CFO
Signature
/s/ Anish John
Issuer symbol
OCX
Transactions as of
01 Jun 2022
Net transactions value
$0
Form type
3
Filing time
13 Jun 2022, 17:50:39 UTC
Next filing
17 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCX Option to Purchase Common Stock 01 Jun 2022 Common Stock 125,000 $3.80 Direct F1
holding OCX Option to Purchase Common Stock 01 Jun 2022 Common Stock 37,500 $1.15 Direct F1
holding OCX Option to Purchase Common Stock 01 Jun 2022 Common Stock 37,500 $1.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options will become exercisable after one year of continuous employment from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continued employment on the applicable vesting dated.
F2 Options vest subject to the Issuer's achievement of pre-defined product and regulatory goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.